Cite
HARVARD Citation
Toyoda, H. et al. (2020). Real‐world experience of 12‐week direct‐acting antiviral regimen of glecaprevir and pibrentasvir in patients with chronic hepatitis C virus infection. Journal of gastroenterology and hepatology. 35 (5), pp. 855-861. [Online].